TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03426098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secret RF
Description: A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
Study: NCT00243997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Becoming Parents Program
Description: Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Becoming Parents Program
Description: Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
Study: NCT03538743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg, twice daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 15 mg twice daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 50 mg twice daily, 28 days
Study: NCT00448175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgent PC Neuromodulation System
Description: The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Study: NCT03538743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 150 mg twice daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 300 mg twice daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 5, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 6, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 7, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 8, 28 days
Study: NCT00421330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Aneurysm Repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair
Study: NCT01758510

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HYNR-CS-Allo
Description: The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\^6 cells/kg, 0.5 X 10\^6 cells/kg, 1 X 10\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\^6 cells/kg dose cohort.
Study: NCT01902979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study: NCT05827757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose-derived mesenchymal stem cell transplantation
Description: Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90
Study: NCT04707755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery technique
Description: The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
Study: NCT01629615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
Study: NCT03952260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting time for clear fluid prior to anaesthesia
Description: This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery.
Study: NCT03623867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will take placebo once weekly in week 0-4, and once monthly till week 48
Study: NCT02809066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sufficient dietary calcium intake in premenstrual syndrome
Description: Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~* 50 gr kashkaval cheese,~* 400 ml milk and~* 150 gr yogurt for each day.
Study: NCT00891826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (EPAX 6015 TG)
Description: The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
Study: NCT03633357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Description: JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-18038683
Description: JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will take two placebo tablets daily, for seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take two placebo tablets daily, for seven days.
Study: NCT02808104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mazindol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mazindol
Study: NCT00544921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug administered
Study: NCT02257424

Intervention type: DRUG
Group type: OTHER
Intervention: Trametinib 2 mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: hydroxychloroquine (HCQ)
Description: hydroxychloroquine (HCQ) is 600 mg orally every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: dabrafenib 150 mg orally twice a day
Study: NCT03128957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVOS cerebral oximeter
Description: Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Licox cerebral oxygenation monitor
Description: Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation
Description: Measuring cerebral oxygenation with varying ventilation strategy
Study: NCT03665038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Administered as IV infusion.
Study: NCT03042000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-NCRT
Description: without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCRT
Description: the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine with oxaliplatin
Description: combined chemotherapy with capecitabine with oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: single-agent chemotherapy with capecitabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEM
Description: transanal endoscopic microsurgery (TEM) excision of the lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical resection
Description: radical resection of rectal cancer
Study: NCT01291017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Description: PD0332991 125 mg PO days 1 - 21
Study: NCT05539846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified blood collection method
Description: The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
Study: NCT03998657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Prostate Treatment
Description: The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
Study: NCT01966770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 1 (ocufilcon D / ocufilcon D)
Description: Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 2 (ocufilcon D / enfilcon A)
Description: Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 3 (ocufilcon D / comfilcon A)
Description: Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 4 (methafilcon A / methafilcon A)
Description: Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 5 (methafilcon A / comfilcon A)
Description: Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 6 (omafilcon A / comfilcon A)
Description: Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
Study: NCT00392184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Study: NCT03075085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WISE (We Inspire Smart Eating)
Description: An enhanced implementation strategy for evidence-based obesity prevention in childcare

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISE (We Inspire Smart Eating)
Description: An enhanced implementation strategy for evidence-based obesity prevention in childcare
Study: NCT00542997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
Description: IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
Study: NCT02326519

Intervention type: OTHER
Group type: OTHER
Intervention: Intracardiac electrode catheter
Description: All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
Study: NCT04133584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 +SIV
Description: Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71
Description: Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SIV
Description: Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
Study: NCT04183985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty prosthesis
Description: In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty prosthesis
Description: In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
Study: NCT02152345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: 1.5 mg/kg IV daily on Day 0-3.~(standard of care)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rATG
Description: 1.5 mg/kg IV daily on Day 0-3.~(standard of care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal transplant
Description: Standard organ transplant of a kidney into a patient with end-stage renal disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal transplant
Description: Standard organ transplant of a kidney into a patient with end-stage renal disease.
Study: NCT03675867

Intervention type: OTHER
Intervention: Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
Description: Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
Study: NCT02644226

Intervention type: OTHER
Intervention: Sevoflurane
Description: The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.

Intervention type: OTHER
Intervention: Desflurane
Description: The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
Study: NCT02554929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taming Sneaky Fears
Description: Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Psycho-education and Child Socialization
Description: Parents receive psycho-education in parent group and children receive socialization skills in child group.
Study: NCT01542645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
Study: NCT03017573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsies / Tumor surgery
Description: Tumoral tissues samples must be collected at different times points :~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)~OR~* before neoadjuvant therapy~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Blood samples must be collected at different times points :~* at the time of surgery or before the beginning of chemoradiotherapy~* after surgery or after chemoradiotherapy~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression~OR~* before neoadjuvant therapy~* during neoadjuvant therapy (post cycle 1)~* at the time of surgery~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression
Study: NCT00605085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis purified inactivated vaccine (IC51)
Description: IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
Study: NCT03171493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-NIS
Description: Attenuated measles virus encoding NIS (MV-NIS)
Study: NCT01382719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bremelanotide
Description: Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bremelanotide
Description: Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bremelanotide
Description: Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
Study: NCT01694004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine Infusion into Duodenum
Study: NCT04206826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREDELFI
Description: It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
Study: NCT03599700

Intervention type: DIAGNOSTIC_TEST
Intervention: myeloproliferative neoplasms
Description: BLOOD SAMPLING